| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V123384 | 17β-HSD5 inhibitor 1 | 243638-37-1 | 17β-HSD5 inhibitor 1 is a potent 17β-HSD5 inhibitor with an IC50 of 2.9 nM in HEK-293 cells overexpressing human 17β-HSD5. |
|
V123385 | 17β-HSD5 inhibitor 2 | 1106941-19-8 | 17β-HSD5 inhibitor 2 is an inhibitor of 17β-hydroxysteroid dehydrogenase 5 (17β-HSD 5) with an IC50 of 40 nM. |
|
V87260 | 17β-HSD5 inhibitor 3 | 948581-46-2 | 17β-HSD5 inhibitor 3 (Compound 31) is an orally active 17β-HSD5 inhibitor with IC50 of 69 nM. |
|
V104587 | 17β-HSD7-IN-1 | 17β-HSD7-IN-1 (Compound 4) is an inhibitor of 17β-HSD7 and inhibits the formation of estradiol (IC50=63 nM). | |
|
V107007 | 3-Acetyl-7-Hydroxycoumarin | 10441-27-7 | 3-Acetyl-7-hydroxycoumarin (Compound 2) is a highly selective 17-β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. |
|
V127364 | 6-Bromocoumarin | 19063-55-9 | 6-Bromocoumarin is a potential antibacterial agent, but it does not inhibit 17β-HSD1. |
|
V127541 | 7-Coumaryl triflate | 108530-10-5 | 7-Coumaryl triflate is a type 1 inhibitor of 17β-hydroxysteroid dehydrogenase. |
|
V110964 | Dehydrofalcarinol | 36150-08-0 | Dehydrofacalol is a polyyne compound found in Candida guatemalense and has anticancer activity. |
|
V87258 | EM 1404 | 243836-37-5 | EM 1404 is a 17β-HSD5 inhibitor (IC50: 3.2 nM). |
|
V135250 | ESC1002755 | 2915567-21-2 | ESC1002755 is a 17β-HSD10 inhibitor with an IC50 of 19 nM. |
|
V136433 | FXR/HSD17B13 modulator 1 | 3067566-36-0 | FXR/HSD17B13 modulator 1 is a potent modulator of FXR/HSD17B13. |
|
V136434 | FXR/HSD17B13-modulator-2 | FXR/HSD17B13-modulator-2 is a dual activator of FXR and an inhibitor of HSD17B13. Its EC50 for human FXR is 128 nM and its IC50 for human HSD17B13 is 0.18 μM. It has high selectivity for the relevant nuclear receptor and HSD17B subtype and is effective orally. | |
|
V116875 | Gatuzosiran | 2409783-34-0 | Gatuzosiran is an siRNA that inhibits the synthesis of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) and is used in research on fatty liver disease. |
|
V116796 | Gatuzosiran sodium | Gatuzosiran sodium is an siRNA that inhibits the synthesis of 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13) and is used in research on fatty liver disease. | |
|
V136859 | GPI2A sodium scrambled negative control | The GPI2A sodium scrambled negative control is a negative control with the GPI2A sodium ion sequence scrambled. | |
|
V83879 | HSD17B13-IN-1 | 2770246-02-9 | |
|
V83979 | HSD17B13-IN-10 | 2576696-23-4 | |
|
V83476 | HSD17B13-IN-100 | 2770246-33-6 | |
|
V83404 | HSD17B13-IN-101 | ||
|
V83526 | HSD17B13-IN-102 | 2770246-34-7 |